Profile data is unavailable for this security.
About the company
Kintara Therapeutics, Inc. is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. It has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.
- Revenue in USD (TTM)0.00
- Net income in USD-9.51m
- Incorporated2009
- Employees2.00
- LocationKintara Therapeutics Inc9920 Pacific Heights BlvdSuite 150, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 350-4364
- Fax+1 (604) 202-1384
- Websitehttps://www.kintara.com/
Mergers & acquisitions
Acquired company | KTRA:NAQ since announced | Transaction value |
---|---|---|
TuHURA Biosciences Inc | 83.70% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GlycoMimetics Inc | 10.00k | -39.11m | 9.85m | 35.00 | -- | 0.4911 | -- | 985.31 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
Curative Biotechnology Inc | 0.00 | -6.02m | 9.94m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
Kiora Pharmaceuticals Inc | 16.02m | 2.67m | 10.22m | 12.00 | -- | 0.3087 | 3.79 | 0.6379 | -7.76 | -7.76 | 6.61 | 11.14 | 0.5279 | -- | 7.16 | 1,335,000.00 | 10.54 | -70.52 | 11.20 | -81.86 | -- | -- | 19.98 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Conduit Pharmaceuticals Inc | 0.00 | -5.17m | 10.22m | 7.00 | -- | -- | -- | -- | -0.0667 | -0.0667 | 0.00 | -0.0738 | 0.00 | -- | -- | 0.00 | -312.39 | -- | -- | -- | -- | -- | -- | -- | -- | -21.32 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
BioVie Inc | 0.00 | -33.01m | 10.30m | 14.00 | -- | 0.515 | -- | -- | -7.92 | -7.92 | 0.00 | 2.51 | 0.00 | -- | -- | 0.00 | -106.51 | -330.64 | -176.17 | -875.72 | -- | -- | -- | -- | -- | -- | 0.2688 | -- | -- | -- | 34.32 | -- | -- | -- |
Kintara Therapeutics Inc | 0.00 | -9.51m | 10.52m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
IN8BIO, Inc. | 0.00 | -31.96m | 10.54m | 31.00 | -- | 0.7677 | -- | -- | -0.8357 | -0.8357 | 0.00 | 0.2933 | 0.00 | -- | -- | 0.00 | -122.41 | -74.18 | -146.35 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0945 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Oncotelic Therapeutics Inc | 70.00k | -1.24m | 10.56m | 22.00 | -- | 0.8711 | -- | 150.90 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
Turnstone Biologics Corp | 0.00 | -74.70m | 10.66m | 82.00 | -- | 0.1785 | -- | -- | -3.49 | -3.49 | 0.00 | 2.58 | 0.00 | -- | -- | 0.00 | -98.52 | -- | -127.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
Senti Biosciences Inc | 338.00k | -78.62m | 10.90m | 48.00 | -- | 0.2465 | -- | 32.24 | -17.52 | -12.65 | 0.0749 | 9.66 | 0.0029 | -- | 1.12 | 7,041.67 | -68.20 | -- | -74.50 | -- | -- | -- | -23,259.47 | -- | -- | -- | 0.0023 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
Tron Pharmaceuticals Inc | 1.01m | -549.47k | 11.04m | 50.00 | -- | -- | -- | 10.94 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
Tenax Therapeutics Inc | 0.00 | -12.57m | 11.18m | 5.00 | -- | 0.7236 | -- | -- | -22.35 | -22.35 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -101.95 | -199.16 | -113.79 | -285.64 | -- | -- | -- | -- | -- | -95.94 | 0.0305 | -- | -- | -- | 30.21 | -- | -- | -- |
BioRestorative Therapies Inc | 174.10k | -8.00m | 11.42m | 11.00 | -- | 1.06 | -- | 65.58 | -1.22 | -1.22 | 0.029 | 1.56 | 0.0118 | -- | 6.65 | 15,827.27 | -54.42 | -192.11 | -68.75 | -329.32 | 47.45 | -- | -4,597.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
Brainstorm Cell Therapeutics Inc | 0.00 | -12.75m | 11.43m | 29.00 | -- | -- | -- | -- | -3.36 | -3.36 | 0.00 | -0.6642 | 0.00 | -- | -- | 0.00 | -223.03 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
Dominari Holdings Inc | 9.51m | -22.02m | 11.49m | 26.00 | -- | 0.2698 | -- | 1.21 | -3.85 | -3.85 | 1.67 | 6.78 | 0.1629 | -- | 2.60 | 365,730.80 | -37.71 | -26.82 | -39.96 | -27.45 | -- | -- | -231.55 | -3,353.52 | -- | -5.05 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
Holder | Shares | % Held |
---|---|---|
Geode Capital Management LLCas of 30 Jun 2024 | 343.91k | 0.62% |
UBS Securities LLCas of 31 Mar 2024 | 138.63k | 0.25% |
G1 Execution Services LLCas of 31 Mar 2024 | 100.79k | 0.18% |
HRT Financial LLCas of 31 Mar 2024 | 81.60k | 0.15% |
Jane Street Capital LLCas of 31 Mar 2024 | 69.36k | 0.13% |
Level Four Advisory Services LLCas of 30 Jun 2024 | 44.64k | 0.08% |
Baader Bank AG (Investment Management)as of 30 Jun 2024 | 42.67k | 0.08% |
Clear Creek Financial Management LLCas of 30 Jun 2024 | 27.50k | 0.05% |
Tower Research Capital LLCas of 31 Mar 2024 | 18.31k | 0.03% |
Nantahala Capital Management LLCas of 31 Mar 2024 | 12.76k | 0.02% |